{"data":[{"accessionNo":"0001104659-26-096755","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001840233","issuerName":"Xilio Therapeutics, Inc.","ticker":"XLO","cusip":"98422T209","securityClass":"Common stock, par value $0.0001 per share","eventDate":"2026-06-30","reportingPerson":"StemPoint Capital Management GP LLC","reportingCik":null,"personType":"OO","sharesOwned":628866,"percentOfClass":9.5,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/xlo"},{"accessionNo":"0001104659-26-096755","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001840233","issuerName":"Xilio Therapeutics, Inc.","ticker":"XLO","cusip":"98422T209","securityClass":"Common stock, par value $0.0001 per share","eventDate":"2026-06-30","reportingPerson":"StemPoint Capital LP","reportingCik":null,"personType":"IA,PN","sharesOwned":628866,"percentOfClass":9.5,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/xlo"},{"accessionNo":"0001104659-26-096755","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001840233","issuerName":"Xilio Therapeutics, Inc.","ticker":"XLO","cusip":"98422T209","securityClass":"Common stock, par value $0.0001 per share","eventDate":"2026-06-30","reportingPerson":"Michelle Ross","reportingCik":null,"personType":"HC,IN","sharesOwned":628866,"percentOfClass":9.5,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/xlo"},{"accessionNo":"0001193125-26-226925","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001840233","issuerName":"Xilio Therapeutics, Inc.","ticker":"XLO","cusip":"98422T209","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"BCLS II Equity Opportunities, LP","reportingCik":null,"personType":"PN","sharesOwned":664021,"percentOfClass":9.99,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/xlo"},{"accessionNo":"0000947871-26-000552","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001840233","issuerName":"Xilio Therapeutics, Inc.","ticker":"XLO","cusip":"28422T209","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"ORBIMED ADVISORS LLC","reportingCik":null,"personType":"IA","sharesOwned":642000,"percentOfClass":9.99,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/xlo"},{"accessionNo":"0000919574-26-003213","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001840233","issuerName":"Xilio Therapeutics, Inc.","ticker":"XLO","cusip":"98422T100","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Sirenia Capital Management LP","reportingCik":null,"personType":"IA,PN","sharesOwned":1142862,"percentOfClass":9.9,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/xlo"},{"accessionNo":"0000919574-26-003213","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001840233","issuerName":"Xilio Therapeutics, Inc.","ticker":"XLO","cusip":"98422T100","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Alex Silverstein","reportingCik":null,"personType":"HC,IN","sharesOwned":1142862,"percentOfClass":9.9,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/xlo"},{"accessionNo":"0000947871-26-000552","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001840233","issuerName":"Xilio Therapeutics, Inc.","ticker":"XLO","cusip":"28422T209","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"OrbiMed Capital GP X LLC","reportingCik":null,"personType":"OO","sharesOwned":481500,"percentOfClass":7.49,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/xlo"},{"accessionNo":"0001193125-26-226925","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001840233","issuerName":"Xilio Therapeutics, Inc.","ticker":"XLO","cusip":"98422T209","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Bain Capital Life Sciences Fund II, L.P.","reportingCik":null,"personType":"PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/xlo"},{"accessionNo":"0001193125-26-226925","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001840233","issuerName":"Xilio Therapeutics, Inc.","ticker":"XLO","cusip":"98422T209","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"BCIP Life Sciences Associates, LP","reportingCik":null,"personType":"PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/xlo"},{"accessionNo":"0000919574-26-003488","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001840233","issuerName":"Xilio Therapeutics, Inc.","ticker":"XLO","cusip":"98422T100","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Point72 Asset Management, L.P.","reportingCik":null,"personType":"PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/xlo"},{"accessionNo":"0000919574-26-003488","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001840233","issuerName":"Xilio Therapeutics, Inc.","ticker":"XLO","cusip":"98422T100","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Point72 Capital Advisors, Inc.","reportingCik":null,"personType":"CO","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/xlo"},{"accessionNo":"0000919574-26-003488","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001840233","issuerName":"Xilio Therapeutics, Inc.","ticker":"XLO","cusip":"98422T100","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Steven A. Cohen","reportingCik":null,"personType":"IN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/xlo"},{"accessionNo":"0001193125-26-054804","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001840233","issuerName":"Xilio Therapeutics, Inc.","ticker":"XLO","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"BCLS II Equity Opportunities, LP","reportingCik":null,"personType":"PN","sharesOwned":6259742,"percentOfClass":8.5,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/xlo"},{"accessionNo":"0001104659-26-015985","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001840233","issuerName":"Xilio Therapeutics, Inc.","ticker":"XLO","cusip":null,"securityClass":"Common stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"StemPoint Capital LP","reportingCik":null,"personType":"IA","sharesOwned":6030028,"percentOfClass":8.4,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/xlo"},{"accessionNo":"0001104659-26-015985","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001840233","issuerName":"Xilio Therapeutics, Inc.","ticker":"XLO","cusip":null,"securityClass":"Common stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"StemPoint Capital Management GP LLC","reportingCik":null,"personType":"OO","sharesOwned":6030028,"percentOfClass":8.4,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/xlo"},{"accessionNo":"0001104659-26-015985","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001840233","issuerName":"Xilio Therapeutics, Inc.","ticker":"XLO","cusip":null,"securityClass":"Common stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"Michelle Ross","reportingCik":null,"personType":"HC,IN","sharesOwned":6030028,"percentOfClass":8.4,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/xlo"},{"accessionNo":"0001193125-26-054804","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001840233","issuerName":"Xilio Therapeutics, Inc.","ticker":"XLO","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"Bain Capital Life Sciences Fund II, L.P.","reportingCik":null,"personType":"PN","sharesOwned":992111,"percentOfClass":1.3,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/xlo"},{"accessionNo":"0001193125-26-054804","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001840233","issuerName":"Xilio Therapeutics, Inc.","ticker":"XLO","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"BCIP Life Sciences Associates, LP","reportingCik":null,"personType":"PN","sharesOwned":120833,"percentOfClass":0.2,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/xlo"},{"accessionNo":"0001193125-26-054804","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001840233","issuerName":"Xilio Therapeutics, Inc.","ticker":"XLO","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"BCLS II Investco, LP","reportingCik":null,"personType":"PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/xlo"},{"accessionNo":"0001231919-26-000149","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001840233","issuerName":"Xilio Therapeutics, Inc.","ticker":"XLO","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"FHMLSP, L.P.","reportingCik":null,"personType":"PN","sharesOwned":4676472,"percentOfClass":6.7,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/xlo"},{"accessionNo":"0001231919-26-000149","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001840233","issuerName":"Xilio Therapeutics, Inc.","ticker":"XLO","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"Frazier Life Sciences Public Fund, L.P.","reportingCik":null,"personType":"PN","sharesOwned":4676472,"percentOfClass":6.7,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/xlo"},{"accessionNo":"0001231919-26-000149","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001840233","issuerName":"Xilio Therapeutics, Inc.","ticker":"XLO","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"FHMLSP, L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":4676472,"percentOfClass":6.7,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/xlo"},{"accessionNo":"0001231919-26-000149","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001840233","issuerName":"Xilio Therapeutics, Inc.","ticker":"XLO","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"FHMLS XII, L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":692657,"percentOfClass":1,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/xlo"},{"accessionNo":"0001231919-26-000149","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001840233","issuerName":"Xilio Therapeutics, Inc.","ticker":"XLO","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"FHMLS XII, L.P.","reportingCik":null,"personType":"PN","sharesOwned":692657,"percentOfClass":1,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/xlo"},{"accessionNo":"0001231919-26-000149","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001840233","issuerName":"Xilio Therapeutics, Inc.","ticker":"XLO","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"Frazier Life Sciences XII, L.P.","reportingCik":null,"personType":"PN","sharesOwned":692657,"percentOfClass":1,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/xlo"},{"accessionNo":"0001231919-26-000149","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001840233","issuerName":"Xilio Therapeutics, Inc.","ticker":"XLO","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"FHMLS XI, L.P.","reportingCik":null,"personType":"PN","sharesOwned":396902,"percentOfClass":0.6,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/xlo"},{"accessionNo":"0001231919-26-000149","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001840233","issuerName":"Xilio Therapeutics, Inc.","ticker":"XLO","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"Frazier Life Sciences XI, L.P.","reportingCik":null,"personType":"PN","sharesOwned":396902,"percentOfClass":0.6,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/xlo"},{"accessionNo":"0001231919-26-000149","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001840233","issuerName":"Xilio Therapeutics, Inc.","ticker":"XLO","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"FHMLS XI, L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":396902,"percentOfClass":0.6,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/xlo"},{"accessionNo":"0001231919-26-000149","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001840233","issuerName":"Xilio Therapeutics, Inc.","ticker":"XLO","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"FHMLS X, L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":149060,"percentOfClass":0.2,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/xlo"},{"accessionNo":"0001231919-26-000149","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001840233","issuerName":"Xilio Therapeutics, Inc.","ticker":"XLO","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"FHMLS X, L.P.","reportingCik":null,"personType":"PN","sharesOwned":149060,"percentOfClass":0.2,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/xlo"},{"accessionNo":"0001231919-26-000149","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001840233","issuerName":"Xilio Therapeutics, Inc.","ticker":"XLO","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"Frazier Life Sciences X, L.P.","reportingCik":null,"personType":"PN","sharesOwned":149060,"percentOfClass":0.2,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/xlo"},{"accessionNo":"0001231919-26-000149","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001840233","issuerName":"Xilio Therapeutics, Inc.","ticker":"XLO","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"Patrick J. Heron","reportingCik":null,"personType":"IN","sharesOwned":149060,"percentOfClass":0.2,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/xlo"},{"accessionNo":"0001231919-26-000149","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001840233","issuerName":"Xilio Therapeutics, Inc.","ticker":"XLO","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"James N. Topper","reportingCik":null,"personType":"IN","sharesOwned":149060,"percentOfClass":0.2,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/xlo"},{"accessionNo":"0001123292-26-000166","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001840233","issuerName":"Xilio Therapeutics, Inc.","ticker":"XLO","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"GILEAD SCIENCES, INC.","reportingCik":null,"personType":"CO","sharesOwned":14517678,"percentOfClass":19.9,"filedAt":"2026-02-12","canonicalUrl":"https://xoomar.com/markets/stocks/xlo"},{"accessionNo":"0001104659-25-120365","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001840233","issuerName":"Xilio Therapeutics, Inc.","ticker":"XLO","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-04","reportingPerson":"Coastlands Capital LP","reportingCik":null,"personType":"IA,PN","sharesOwned":5346069,"percentOfClass":9.99,"filedAt":"2025-12-11","canonicalUrl":"https://xoomar.com/markets/stocks/xlo"},{"accessionNo":"0001104659-25-120365","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001840233","issuerName":"Xilio Therapeutics, Inc.","ticker":"XLO","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-04","reportingPerson":"Coastlands Capital Partners LP","reportingCik":null,"personType":"PN","sharesOwned":5346069,"percentOfClass":9.99,"filedAt":"2025-12-11","canonicalUrl":"https://xoomar.com/markets/stocks/xlo"},{"accessionNo":"0001104659-25-120365","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001840233","issuerName":"Xilio Therapeutics, Inc.","ticker":"XLO","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-04","reportingPerson":"Coastlands Capital GP LLC","reportingCik":null,"personType":"OO","sharesOwned":5346069,"percentOfClass":9.99,"filedAt":"2025-12-11","canonicalUrl":"https://xoomar.com/markets/stocks/xlo"},{"accessionNo":"0001104659-25-120365","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001840233","issuerName":"Xilio Therapeutics, Inc.","ticker":"XLO","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-04","reportingPerson":"Coastlands Capital LLC","reportingCik":null,"personType":"HC,OO","sharesOwned":5346069,"percentOfClass":9.99,"filedAt":"2025-12-11","canonicalUrl":"https://xoomar.com/markets/stocks/xlo"},{"accessionNo":"0001104659-25-120365","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001840233","issuerName":"Xilio Therapeutics, Inc.","ticker":"XLO","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-04","reportingPerson":"Matthew D. Perry","reportingCik":null,"personType":"HC,IN","sharesOwned":5346069,"percentOfClass":9.99,"filedAt":"2025-12-11","canonicalUrl":"https://xoomar.com/markets/stocks/xlo"},{"accessionNo":"0000902664-25-004986","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001840233","issuerName":"Xilio Therapeutics, Inc.","ticker":"XLO","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-09-30","reportingPerson":"Steven A. Cohen","reportingCik":null,"personType":"IN","sharesOwned":8000000,"percentOfClass":9.9,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/xlo"},{"accessionNo":"0000902664-25-004986","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001840233","issuerName":"Xilio Therapeutics, Inc.","ticker":"XLO","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-09-30","reportingPerson":"Point72 Asset Management, L.P.","reportingCik":null,"personType":"PN","sharesOwned":8000000,"percentOfClass":9.9,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/xlo"},{"accessionNo":"0000902664-25-004986","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001840233","issuerName":"Xilio Therapeutics, Inc.","ticker":"XLO","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-09-30","reportingPerson":"Point72 Capital Advisors, Inc.","reportingCik":null,"personType":"CO","sharesOwned":8000000,"percentOfClass":9.9,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/xlo"},{"accessionNo":"0001104659-25-112051","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001840233","issuerName":"Xilio Therapeutics, Inc.","ticker":"XLO","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-09-30","reportingPerson":"StemPoint Capital LP","reportingCik":null,"personType":"IA","sharesOwned":4000000,"percentOfClass":7.2,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/xlo"},{"accessionNo":"0001104659-25-112051","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001840233","issuerName":"Xilio Therapeutics, Inc.","ticker":"XLO","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-09-30","reportingPerson":"StemPoint Capital Management GP LLC","reportingCik":null,"personType":"CO","sharesOwned":4000000,"percentOfClass":7.2,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/xlo"},{"accessionNo":"0001104659-25-112051","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001840233","issuerName":"Xilio Therapeutics, Inc.","ticker":"XLO","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-09-30","reportingPerson":"Michelle Ross","reportingCik":null,"personType":"IN","sharesOwned":4000000,"percentOfClass":7.2,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/xlo"}],"updatedAt":"2026-11-04T06:03:58.517Z","source":"xoomar.com","docs":"https://xoomar.com/markets/api","license":"https://xoomar.com/terms","attribution":"Credit XOOMAR with a link to the dataset page on xoomar.com when you republish this data","canonicalUrl":"https://xoomar.com/markets/stocks/xlo","meta":{"source":"SEC","sourceAttribution":"Schedule 13D and 13G data: SEC.","notice":"10 requests a minute without a key, 30 with a free key. Get a free key at https://xoomar.com/signup?utm_source=api, register your app at https://xoomar.com/developers/register?utm_source=api, and credit the data as \"Data: XOOMAR\" together with the sourceAttribution line."}}